Wuhan Healthgen Biotechnology Corp. (SHA:688765)

China · Delayed Price · Currency is CNY

30.40

+1.81 (6.33%)

At close: Oct 30, 2026

Market Cap	10.87B -73.1%
Revenue (ttm)	23.39M -3.6%
Net Income	-160.81M
EPS	-0.60
Shares Out	357.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,104,814
Open	28.14
Previous Close	28.59
Day's Range	28.14 - 32.23
52-Week Range	26.97 - 132.03
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About SHA:688765

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial, recombinant human keratinocyte growth factor, recombinant human fibronectin, ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2006

Employees 215

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688765

Full Company Profile

Financial Performance

In 2024, SHA:688765's revenue was 25.22 million, an increase of 3.92% compared to the previous year's 24.26 million. Losses were -151.37 million, -19.04% less than in 2023.

Financial Statements